Eli Lilly Sues Glenmark Over Cancer Drug ANDA
Lilly claims that Glenmark's proposed generic Alimta infringes its U.S. Patent Number 7,772,209, which covers a method of administering pemetrexed disodium — Alimta's active ingredient — along with folic acid and vitamin B12.
Thursday's suit was the latest in a string of actions Lilly has filed to enforce the '209 patent since it...
Already a subscriber? Click here to login